Pailin Biotech: Legal Opinion of Beijing Jiayuan Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Paisi Shuanglin Biopharmaceutical Co., Ltd.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.